Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.

Autor: Wenzel L; Department of Medicine, Program in Public Health and Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, United States of America. Electronic address: lwenzel@uci.edu., Huang HQ; NRG Oncology Statistics & Data Center, Roswell Park Cancer Institute, Buffalo, NY 14263, United States of America. Electronic address: hhuang@gogstats.org., Cella D; Department of Medical Social Sciences and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60612, United States of America. Electronic address: d-cella@northwestern.edu., McKinney CO; Department of Medicine, Program in Public Health and Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, United States of America. Electronic address: comckinn@uci.edu., Zevon MA; Department of Health Behavior, Roswell Park Cancer Institute, Buffalo, NY 14263, United States of America., LaChance JA; Maine Medical Partners Women's Health Division of Gynecologic Oncology, Scarborough, ME 04074, United States of America. Electronic address: lachaj1@mmc.org., Walker JL; Stephenson Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK, United States of America. Electronic address: joan-walker@ouhsc.edu., Salani R; Division of Gynecologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America. Electronic address: rsalani@mednet.ucla.edu., Modesitt SC; Gynecologic Oncology Division, OB/GYN Department, University of Virginia, Charlottesville, VA 22908, United States of America. Electronic address: scm6h@virginia.edu., Morris RT; Gynecologic Oncology Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, United States of America. Electronic address: rmorris@med.wayne.edu., Bradley WH; Department of OB/GYN, Medical College of Wisconsin, Milwaukee, WI 53226, United States of America. Electronic address: wbradley@mcw.edu., Boente MP; U.S. Medical Affairs, Gyn-Oncology, Genentech, South San Francisco, CA 94080, United States of America. Electronic address: boente.matthew@gene.com., von Gruenigen VE; Division of Gynecologic Oncology, Summa Health System, NEOMED, Akron, OH 44310, United States of America. Electronic address: vongruev@summahealth.org.
Jazyk: angličtina
Zdroj: Gynecologic oncology [Gynecol Oncol] 2021 Nov; Vol. 163 (2), pp. 392-397. Date of Electronic Publication: 2021 Sep 20.
DOI: 10.1016/j.ygyno.2021.08.028
Abstrakt: Objectives: In a prospective study of platinum-resistant ovarian cancer patients, we examined whether the Disease-related Symptoms-Physical (DRS--P) scale of the NCCN/FACT-Ovarian Cancer Symptom Index-18 (NFOSI-18) is responsive to clinical change in patients estimated by their provider to survive at least six months.
Methods: The NFOSI-18, and other FACT measures, was collected at study entry and 3 and 6 months post-enrollment. Measures were compared for those who died or dropped off study prior to 3 months or prior to 6 months (assumed as health deterioration over time), or those who stayed on study through 6 months (presumed as stable disease over time). Statistical analyses included a fitted linear mixed model for estimating the group differences over time, Cox regression to assess the probability of survival with patient-reported outcomes, and effect size.
Results: DRS-P scores of patients who completed only one assessment were significantly lower compared to patients who were able to complete two assessments [5.9 points lower (2.0-9.8); p < 0.01], or three assessments [8.1 points lower (4.8-11.5); p < 0.01]. Measures of abdominal discomfort, functional well-being, emotional well-being, and quality of life were also significant, but treatment side effects were not. Further, in every scale except for neurotoxicity, higher (better) baseline scores were associated with a decreased likelihood of death, after adjusting for age, performance and disease status.
Conclusion: The NFOSI-18 DRS-P scale is responsive to clinical change. It has potential as an indicator of changing health status with ovarian cancer disease progression, distinct from treatment side effects.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: